Brokerages Set Roivant Sciences Ltd. (NASDAQ:ROIV) Target Price at $33.59

Roivant Sciences Ltd. (NASDAQ:ROIV) has been given a consensus recommendation of “Moderate Buy” by the twelve analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $33.5909.

A number of analysts recently issued reports on the company. TD Cowen upped their target price on Roivant Sciences from $38.00 to $41.00 and gave the company a “buy” rating in a research report on Thursday, May 21st. Piper Sandler reiterated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, May 21st. Citigroup raised their target price on shares of Roivant Sciences from $35.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, May 21st. Weiss Ratings cut shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $34.00 price target on shares of Roivant Sciences in a research report on Thursday, May 21st.

Roivant Sciences Stock Performance

Shares of ROIV stock opened at $35.01 on Friday. The stock’s 50-day moving average is $32.24 and its two-hundred day moving average is $28.67. The firm has a market cap of $25.18 billion, a price-to-earnings ratio of -58.35 and a beta of 1.11. Roivant Sciences has a 1 year low of $10.90 and a 1 year high of $37.00.

Insider Buying and Selling at Roivant Sciences

In related news, Director Daniel Allen Gold sold 800,000 shares of the firm’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $34.55, for a total transaction of $27,640,000.00. Following the transaction, the director owned 13,701,546 shares of the company’s stock, valued at $473,388,414.30. This trade represents a 5.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $33.16, for a total value of $6,632,000.00. Following the completion of the transaction, the chief executive officer owned 1,613,063 shares in the company, valued at $53,489,169.08. This trade represents a 11.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 1,855,913 shares of company stock worth $62,649,633. 10.80% of the stock is owned by company insiders.

Institutional Trading of Roivant Sciences

Hedge funds have recently added to or reduced their stakes in the stock. SBI Securities Co. Ltd. increased its holdings in shares of Roivant Sciences by 1,740.3% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after purchasing an additional 1,166 shares during the period. Allworth Financial LP lifted its holdings in shares of Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after purchasing an additional 583 shares during the period. Kestra Advisory Services LLC acquired a new stake in shares of Roivant Sciences during the fourth quarter worth $47,000. Parallel Advisors LLC grew its position in Roivant Sciences by 33.7% in the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock valued at $57,000 after buying an additional 520 shares during the last quarter. Finally, CIBC Private Wealth Group LLC grew its position in Roivant Sciences by 7,614.3% in the 4th quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock valued at $59,000 after buying an additional 2,665 shares during the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.